Quest Diagnostics Added as Short Idea by Hedgeye with 20% Downside Potential
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 23 2026
0mins
Source: seekingalpha
- Short Idea Shift: Hedgeye has added Quest Diagnostics (DGX) as a new short idea, projecting a downside potential of 20%, reflecting analysts' concerns about the company's future growth, particularly facing tough comps in Q2 2026.
- Growth Deceleration Outlook: Analyst Tom Tobin noted that while management's guidance for Q1 2026 aligns with expectations, the market still models approximately 4% growth and margin expansion, which may be overly optimistic as growth normalizes sooner than anticipated.
- Valuation Pressure: Despite Quest Diagnostics' elevated valuation of 12.2x EV/EBITDA compared to the industry average of 10.7x, analysts believe there is up to a 20% downside risk, especially if estimates are cut due to decelerating growth.
- Key Catalysts: Future key catalysts include Q2 2026 performance, a reset of 2027 guidance, and any slowdown in partnership channels, all of which will directly impact the company's market performance and investor confidence.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy DGX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on DGX
Wall Street analysts forecast DGX stock price to rise
5 Analyst Rating
3 Buy
2 Hold
0 Sell
Moderate Buy
Current: 192.880
Low
190.00
Averages
203.33
High
210.00
Current: 192.880
Low
190.00
Averages
203.33
High
210.00
About DGX
Quest Diagnostics Incorporated is a provider of diagnostic information services. It provides diagnostic insights from the results of its laboratory testing to empower people, physicians, and organizations to take action to improve health outcomes. It operates through the DIS segment, which provides diagnostic information services to a range of customers within its primary customer channels: physicians, hospitals, and patients and consumers. It offers broad access to clinical testing through a nationwide network of laboratories, patient service centers, phlebotomists in physician offices, and its connectivity resources, including call centers and mobile phlebotomists, nurses and other health and wellness professionals. Its other customers include health plans, employers, emerging retail healthcare providers, government agencies, and others. Its services are provided under the Quest Diagnostics brand and under other brands, including AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Quest Diagnostics Declares Quarterly Dividend of $0.86 per Share
- Quarterly Dividend Announcement: Quest Diagnostics has declared a quarterly dividend of $0.86 per share, consistent with previous distributions, indicating the company's stable cash flow and profitability.
- Dividend Yield: The forward yield of 1.81% reflects the company's attractiveness in the current market environment, potentially drawing in more income-focused investors.
- Payment Schedule: The dividend is payable on July 22, with a record date of July 8 and an ex-dividend date also set for July 8, ensuring shareholders receive their earnings promptly.
- Market Reaction Expectations: With the stable dividend issuance, a positive impact on the company's stock price is anticipated, enhancing investor confidence and potentially driving the stock price upward.
See More
Quest Diagnostics Declares Quarterly Cash Dividend
- Quarterly Cash Dividend: Quest Diagnostics' Board of Directors declared a cash dividend of $0.86 per share, payable on July 22, 2026, reflecting the company's stable financial position and commitment to shareholder returns.
- Record Date for Shareholders: The record date for this dividend is set for July 8, 2026, ensuring that shareholders holding stock before this date will receive the dividend, which further boosts investor confidence.
- Market Impact: As a leader in diagnostic information services, Quest Diagnostics serves one in three American adults annually, and the dividend announcement may attract more investor interest in its stock, enhancing market liquidity.
- Company Vision: Quest Diagnostics is dedicated to improving healthcare management and healthy behaviors through smarter, simpler testing services, and the dividend declaration aligns with its long-term strategic goals to strengthen its leadership position in the healthcare industry.
See More
2026 Market Cap Madness Championship Recap
- Championship Showdown: The 2026 Market Cap Madness Championship featured Emily Flippen facing off against undefeated challenger Loren Horst, showcasing intense competition that captivated many investors.
- Game Mechanics: Contestants were required to provide market cap ranges for randomly mentioned stocks, scoring points by agreeing or disagreeing, highlighting the significance of market caps in investment decisions.
- Stock Performance Analysis: During the game, Texas Instruments' market cap was assessed at $177.50 billion, underscoring its strong position in the semiconductor industry and reflecting investor confidence in its future growth.
- Final Outcome: Emily emerged victorious with an 8-2 score, solidifying her status as the Market Cap Game Show World Champion, emphasizing her keen insights into market dynamics and effective investment strategies.
See More
Quest Diagnostics Prices $500 Million Senior Notes Offering
- Offering Size: Quest Diagnostics announced the pricing of $500 million in senior notes at a 5% interest rate, expected to close on May 6, 2026, providing the company with substantial funding to support its operations and growth.
- Debt Management: The net proceeds from this offering will be used for general corporate purposes, including potential repayment of maturing 3.45% notes, indicating the company's strategic intent to optimize its capital structure and reduce financial costs.
- Market Reaction: Following the announcement, Quest Diagnostics' stock price dipped 0.49% in after-hours trading to $195.65, reflecting market caution regarding the new debt issuance.
- Performance Outlook: Quest Diagnostics raised its 2026 revenue guidance to between $11.78 billion and $11.9 billion, with adjusted EPS expectations of $10.63 to $10.83, demonstrating the company's confidence in future performance and growth potential.
See More
Quest Diagnostics Prices $500 Million Senior Notes Offering
- Offering Overview: Quest Diagnostics announced the pricing of $500 million in senior notes at a 5.000% interest rate, expected to close on May 6, 2026, indicating the company's active engagement in capital markets and financing capabilities.
- Clear Use of Proceeds: The net proceeds from this offering will be utilized for general corporate purposes, including the repayment of $500 million in 3.45% senior notes maturing on June 1, 2026, aimed at optimizing the company's capital structure and reducing financial costs.
- Positive Market Response: The issuance of these notes has garnered attention in the market, reflecting investor confidence in Quest Diagnostics, which may enhance the company's competitive position in the medical diagnostics sector.
- Cautious Future Outlook: Despite demonstrating strong financing capabilities, the company must remain vigilant regarding economic volatility and regulatory changes that could impact future performance, ensuring ongoing financial health and market standing.
See More
Quest Diagnostics Added as Short Idea by Hedgeye with 20% Downside Potential
- Short Idea Shift: Hedgeye has added Quest Diagnostics (DGX) as a new short idea, projecting a downside potential of 20%, reflecting analysts' concerns about the company's future growth, particularly facing tough comps in Q2 2026.
- Growth Deceleration Outlook: Analyst Tom Tobin noted that while management's guidance for Q1 2026 aligns with expectations, the market still models approximately 4% growth and margin expansion, which may be overly optimistic as growth normalizes sooner than anticipated.
- Valuation Pressure: Despite Quest Diagnostics' elevated valuation of 12.2x EV/EBITDA compared to the industry average of 10.7x, analysts believe there is up to a 20% downside risk, especially if estimates are cut due to decelerating growth.
- Key Catalysts: Future key catalysts include Q2 2026 performance, a reset of 2027 guidance, and any slowdown in partnership channels, all of which will directly impact the company's market performance and investor confidence.
See More
Quest Diagnostics Declares Quarterly Dividend of $0.86 per Share
- Quarterly Dividend Announcement: Quest Diagnostics has declared a quarterly dividend of $0.86 per share, consistent with previous distributions, indicating the company's stable cash flow and profitability.
- Dividend Yield: The forward yield of 1.81% reflects the company's attractiveness in the current market environment, potentially drawing in more income-focused investors.
- Payment Schedule: The dividend is payable on July 22, with a record date of July 8 and an ex-dividend date also set for July 8, ensuring shareholders receive their earnings promptly.
- Market Reaction Expectations: With the stable dividend issuance, a positive impact on the company's stock price is anticipated, enhancing investor confidence and potentially driving the stock price upward.
See More
Quest Diagnostics Declares Quarterly Cash Dividend
- Quarterly Cash Dividend: Quest Diagnostics' Board of Directors declared a cash dividend of $0.86 per share, payable on July 22, 2026, reflecting the company's stable financial position and commitment to shareholder returns.
- Record Date for Shareholders: The record date for this dividend is set for July 8, 2026, ensuring that shareholders holding stock before this date will receive the dividend, which further boosts investor confidence.
- Market Impact: As a leader in diagnostic information services, Quest Diagnostics serves one in three American adults annually, and the dividend announcement may attract more investor interest in its stock, enhancing market liquidity.
- Company Vision: Quest Diagnostics is dedicated to improving healthcare management and healthy behaviors through smarter, simpler testing services, and the dividend declaration aligns with its long-term strategic goals to strengthen its leadership position in the healthcare industry.
See More
2026 Market Cap Madness Championship Recap
- Championship Showdown: The 2026 Market Cap Madness Championship featured Emily Flippen facing off against undefeated challenger Loren Horst, showcasing intense competition that captivated many investors.
- Game Mechanics: Contestants were required to provide market cap ranges for randomly mentioned stocks, scoring points by agreeing or disagreeing, highlighting the significance of market caps in investment decisions.
- Stock Performance Analysis: During the game, Texas Instruments' market cap was assessed at $177.50 billion, underscoring its strong position in the semiconductor industry and reflecting investor confidence in its future growth.
- Final Outcome: Emily emerged victorious with an 8-2 score, solidifying her status as the Market Cap Game Show World Champion, emphasizing her keen insights into market dynamics and effective investment strategies.
See More
Quest Diagnostics Prices $500 Million Senior Notes Offering
- Offering Size: Quest Diagnostics announced the pricing of $500 million in senior notes at a 5% interest rate, expected to close on May 6, 2026, providing the company with substantial funding to support its operations and growth.
- Debt Management: The net proceeds from this offering will be used for general corporate purposes, including potential repayment of maturing 3.45% notes, indicating the company's strategic intent to optimize its capital structure and reduce financial costs.
- Market Reaction: Following the announcement, Quest Diagnostics' stock price dipped 0.49% in after-hours trading to $195.65, reflecting market caution regarding the new debt issuance.
- Performance Outlook: Quest Diagnostics raised its 2026 revenue guidance to between $11.78 billion and $11.9 billion, with adjusted EPS expectations of $10.63 to $10.83, demonstrating the company's confidence in future performance and growth potential.
See More
Quest Diagnostics Prices $500 Million Senior Notes Offering
- Offering Overview: Quest Diagnostics announced the pricing of $500 million in senior notes at a 5.000% interest rate, expected to close on May 6, 2026, indicating the company's active engagement in capital markets and financing capabilities.
- Clear Use of Proceeds: The net proceeds from this offering will be utilized for general corporate purposes, including the repayment of $500 million in 3.45% senior notes maturing on June 1, 2026, aimed at optimizing the company's capital structure and reducing financial costs.
- Positive Market Response: The issuance of these notes has garnered attention in the market, reflecting investor confidence in Quest Diagnostics, which may enhance the company's competitive position in the medical diagnostics sector.
- Cautious Future Outlook: Despite demonstrating strong financing capabilities, the company must remain vigilant regarding economic volatility and regulatory changes that could impact future performance, ensuring ongoing financial health and market standing.
See More
Quest Diagnostics Added as Short Idea by Hedgeye with 20% Downside Potential
- Short Idea Shift: Hedgeye has added Quest Diagnostics (DGX) as a new short idea, projecting a downside potential of 20%, reflecting analysts' concerns about the company's future growth, particularly facing tough comps in Q2 2026.
- Growth Deceleration Outlook: Analyst Tom Tobin noted that while management's guidance for Q1 2026 aligns with expectations, the market still models approximately 4% growth and margin expansion, which may be overly optimistic as growth normalizes sooner than anticipated.
- Valuation Pressure: Despite Quest Diagnostics' elevated valuation of 12.2x EV/EBITDA compared to the industry average of 10.7x, analysts believe there is up to a 20% downside risk, especially if estimates are cut due to decelerating growth.
- Key Catalysts: Future key catalysts include Q2 2026 performance, a reset of 2027 guidance, and any slowdown in partnership channels, all of which will directly impact the company's market performance and investor confidence.
See More
